

Firm: We are an independent, global equity boutique investing in high-quality growth companies at value prices.

- **Philosophy:** We believe earnings growth drives stock performance over time and that there are short term inefficiencies in the market that can create attractive entry points. For over three decades, we have followed a focused and disciplined investment process that results in concentrated, high conviction portfolios with high active share.
- **Strategy:** We adhere to a disciplined philosophy and process and consistently apply this along with deep fundamental research in our stock selection. The portfolio typically will invest in 30 to 35 companies located primarily in the United States with selective use of ADRs for companies located outside the United States.

COMPOSITE PERFORMANCE ¹ (%) (period ending June 30, 2022)							
	2nd QTR	YTD	1 Year	3 Years	5 Years	10 Years	Inception
Select Equity (gross of fees)	-16.00	-19.94	-12.87	11.47	11.60	13.37	12.84
Select Equity (net of fees)	-16.12	-20.19	-13.41	10.79	10.92	12.65	12.16
S&P 500 Total Return Index	-16.10	-19.96	-10.62	10.59	11.30	12.91	10.24
Russell 1000 Growth Index	-20.92	-28.07	-18.77	12.57	14.28	14.79	10.34

GENERAL INFORMATION ²		GROWTH OF \$10,000 SINCE INCEPTION ³
Strategy Assets	\$319.9 million	\$500,000 Select Equity Composite (net)
Firm Assets	\$6,772.6 million	\$400,000 - S&P 500 Total Return Index
Strategy Benchmark	S&P 500 TR	\$300,000 -
Number of Positions	31	\$200,000 - \$215,773
% in Top 10	43.2	\$100,000
Active Share (%)	78.1	\$0
Composite Inception Date	Dec-1990	1990 1994 1998 2002 2006 2010 2014 2018

PORTFOLIO CHARACTERISTICS⁴	HJ SELECT	S&P 500
Weighted Average Market Cap. (\$B)	380.2	483.9
Median Market Cap. (\$B)	72.0	27.2
EPS Growth: 3 to 5 year forecast (%)	15.5	12.2
EPS Growth: 5 year trailing (%)	15.6	18.7
P/E Ratio: 12 Months - forward	20.1	19.3
P/E Ratio: 12 Months - trailing	33.6	27.9
Return on Equity: 5 Year (%)	22.2	24.6


FIVE LARGEST HOLDINGS (%) HJ SELECT S&P 500 Apple Inc. 5.1 6.6 6.0 Microsoft Corp. 4.7 Alphabet Inc. 4.5 3.9 4.5 Mastercard Inc. 0.9 AstraZeneca plc 4.4 0.0

Refer to important disclosures on page 2.



Hardman Johnston Select Equity 2022 SECOND QUARTER FACT SHEET

SECTOR EXPOSURE⁵ (%)



CONTRIBUTORS & DETRACTORS⁶

Second Quarter	Average	Total
	Weight (%)	Effect ⁷ (%)
Largest Contributors		
Vertex Pharmaceuticals Inc.	3.57	0.65
AstraZeneca plc	4.04	0.58
Albemarle Corp.	3.71	0.35
Largest Detractors		
NVIDIA Corp.	3.59	-0.82
Wolfspeed, Inc.	2.31	-0.78
Universal Display Corp.	2.65	-0.71

General Disclosures:

Preliminary data as of June 30, 2022. Source: FactSet. Hardman Johnston Global Advisors LLC®. Strategy holdings are based on a representative account. (1) Performance is preliminary. Performance greater than one year is annualized. Net performance reflects the deduction of advisory fees. The Russell 1000 Growth Index is shown as supplemental information. **Past performance does not guarantee future results**. The inception date of the composite is December 31, 1990. (2) Active share is calculated in FactSet. Select Equity strategy assets include all derivations of the select equity accounts managed by the firm. In the event the portfolio holds multiple share classes of a company, the total number of positions reflects the multiple share classes as a single position. (3) Performance is based on the cumulative return of the net track record of the composite. Source: Hardman Johnston Global Advisors LLC®. (4) All characteristics are calculated in FactSet. EPS, ROE, and P/E figures reflect interquartile weighted mean. (5) Hardman Johnston Global Advisors LLC® generally uses Global Industry Classification Standard to determine sector classification. Hardman Johnston may reclassify a company into a more suitable sector if it believes that the GICS classification for a specific company does not accurately classify the company from our perspective. (6) Securities reflect the period's three largest contributors and detractors to total effect. Total effect ricludes only securities that were held in the Hardman Johnston representative account and excludes benchmark-only securities that were held in the Hardman Johnston relative results.

Portfolio holdings and/or allocations shown are as of the date indicated and may not be representative of future investments. The holdings and/or allocations shown may not represent all of the portfolio's investments. Future investments may or may not be profitable. Any mention of past investment decisions is intended only to illustrate our investment approach and/or strategy and is not indicative of the performance of the strategy as a whole. It should not be assumed that any investment decisions shown will be profitable, or that any investment decisions made in the future will be profitable or will equal the performance of the investments discussed herein. A complete list of past recommendations is available upon request.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. (MSCI) and Standard & Poor's, a division of the McGraw-HII Companies, Inc. (S&P) and is licensed for use by Hardman Johnston Global Advisors LLC®. Neither MSCI, S&P nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

The information contained herein is confidential and is offered for informational purposes only. The information may not be relied on in any matter as legal, tax or investment advice or as an offer to sell or solicitation to buy an interest in any private funds offered by Hardman Johnston Global Advisors LLC®. Index Benchmarks: Indices are unmanaged. The figures for the index reflect the reinvestment of all income

Last Twelve Months	Average	Total
Last Twelve Month's	Weight (%)	Effect ⁷ (%)
Largest Contributors		
Vertex Pharmaceuticals Inc.	2.75	1.24
Albemarle Corp.	3.57	1.09
AstraZeneca plc	3.51	0.80
Largest Detractors		
Vertiv Holdings Co.	2.76	-2.26
Universal Display Corp.	2.62	-1.46
Stanley Black & Decker Inc.	2.59	-1.18

or dividends, as applicable, but do not reflect the deduction of any fees or expenses which would reduce returns. Investors cannot invest directly in indices. The indices referenced herein have been selected because they are well known, easily recognized by investors, and reflect those indices that Hardman Johnston believes, in part based on industry practice, provide a suitable benchmark against which to evaluate the investment or broader market described herein.